BRILLIANCE trial results showed 11 out of 14 treated participants experienced some improvements in vision and quality of life measures.
CRISPR-based therapy
Massachusetts Eye and Ear in Boston has agreed to pay $5.7 million to settle False Claims Act allegations. Whistleblower will receive 17% of settlement.